DEF 14A: Tyra Biosciences Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals

Tyra Biosciences will hold its annual stockholders meeting virtually on May 29, 2024, to vote on director elections, auditor ratification, and an amendment to the company's certificate of incorporation.

Summary

• Tyra Biosciences will hold its Annual Meeting of Stockholders on May 29, 2024, at 10:00 a.m. Pacific Time, as a virtual meeting.
• Stockholders of record as of April 4, 2024, are entitled to vote.
• The meeting will address the election of three Class III directors, ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and approval of an amendment to the company's certificate of incorporation to permit exculpation of certain officers.
• The Board recommends voting 'FOR' all director nominees, the ratification of Ernst & Young LLP, and the amendment to the certificate of incorporation.
• As of the record date, April 4, 2024, there were 52,523,850 shares of common stock outstanding and entitled to vote.
• The company is furnishing proxy materials electronically via the Internet, with a Notice of Internet Availability sent to most stockholders.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The Board's recommendations to vote 'FOR' all proposals suggest a positive outlook from management's perspective.

Positives

• The company is taking advantage of SEC rules to furnish proxy materials electronically, reducing costs and environmental impact.
• The Board is recommending 'FOR' votes on all proposals, indicating confidence in the nominees and the proposed amendment.
• The company has a diverse board with members bringing significant leadership experience and expertise from various sectors.
• The Audit Committee has pre-approved all audit and non-audit services provided by Ernst & Young LLP, ensuring auditor independence.

Negatives

• The division of the Board into three classes with staggered three-year terms may delay or prevent a change of management or control of the company.
• Directors may only be removed for cause and only by the affirmative vote of the holders of at least two-thirds of the voting power of the then-outstanding shares of capital stock entitled to vote in the election of directors.
• If the organization that holds your shares does not receive instructions from you on how to vote your shares on a non-routine matter, that organization will inform the inspector of election that it does not have the authority to vote on that matter with respect to your shares.

Risks

• The proxy statement notes that directors may only be removed for cause and only by the affirmative vote of the holders of at least two-thirds of the voting power of the then-outstanding shares of capital stock entitled to vote in the election of directors.
• The proposed Officer Exculpation Charter Amendment would allow for the exculpation of covered officers only in connection with direct claims brought by stockholders, including class actions, but would not eliminate officers monetary liability for breach of fiduciary duty claims brought by the Company itself or for derivative claims brought by stockholders in the name of the Company.

Future Outlook

The Board will continue to periodically review our leadership structure and may make such changes in the future as it deems appropriate.

Management Comments

• Todd Harris, President and CEO, urges stockholders to vote and submit their proxy promptly.
• The Board believes it is important to provide protection from certain liabilities and expenses that may discourage prospective or current officers from serving corporations.
• Limiting concern about personal risk would empower both directors and officers to best exercise their business judgment in furtherance of stockholder interests.

Industry Context

The proposal to amend the certificate of incorporation to permit exculpation of certain officers reflects a trend among Delaware companies following the enactment of legislation in August 2022 allowing such exculpation.

Comparison to Industry Standards

• The proxy statement mentions that the Board expects 'our peers to adopt exculpation clauses that limit the personal liability of officers in their certificates of incorporation,' indicating that this is becoming a standard practice in the industry.
• The company's corporate governance practices, such as having a separate Chairman of the Board and independent directors, align with common governance structures in publicly traded companies.

Corporate Governance

Related Party Transactions

• The proxy statement discloses a consulting agreement with van den Boom & Associates, LLC, where payments for accounting resources during the year ending December 31, 2022, were approximately $765,000.
• The document mentions an amended and restated investors rights agreement in March 2021 with holders of convertible preferred stock and certain holders of common stock, including entities with which certain directors are affiliated.
• The document mentions a private placement of shares of Common Stock and pre-funded warrants to purchase shares of Common Stock, with related persons acquiring shares in the placement.

Stakeholder Impact

• Approval of the officer exculpation amendment could impact the company's ability to attract and retain qualified officers.
• The outcome of the votes on the proposals will directly affect stockholders.
• The election of directors will shape the composition of the Board and its oversight of the company.

Next Steps

• Stockholders are encouraged to vote on the proposals.
• The company will file the Officer Exculpation Charter Amendment with the Delaware Secretary of State if approved by stockholders.
• The company intends to file a Proxy Statement and WHITE proxy card with the SEC in connection with the solicitation of proxies for our 2025 annual meeting.

Key Dates

Keywords

proxy statement, annual meeting, directors, stockholders, Ernst & Young, officer exculpation, corporate governance, Tyra Biosciences